Anesthetic implications of the new anticoagulant and antiplatelet drugs

Journal of Clinical Anesthesia

Volumn 20, Issue 3, 2008, Pages 228-237

  Vitin, Alexander A ^a   Dembo, Gregory ^a   Vater, Youri ^a   Martay, Kenneth ^a   Azamfirei, Leonard ^d   Ezri, Tiberiu ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WOLFSON MEDICAL CENTER   (Israel)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Anticoagulant antiplatelet drugs; Neuraxial anesthesia; Regional anesthesia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANCROD; ANESTHETIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARDEPARIN; ARGATROBAN; BEMIPARIN; CLOPIDOGREL; DALTEPARIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE INHIBITOR; REVIPARIN; THROMBIN INHIBITOR; TICLOPIDINE; TINZAPARIN; TIROFIBAN; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANAPHYLAXIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CENTRAL VENOUS CATHETERIZATION; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EPISTAXIS; HEART MUSCLE ISCHEMIA; HEMATOMA; HEMATURIA; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; NEUROLOGIC DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS; REGIONAL ANESTHESIA; RISK FACTOR; SPINAL HEMATOMA; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EID: 43849095258     PISSN: 09528180     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinane.2007.10.013     Document Type: Article

References (158)

1. B.E. Ickx Preoperative stop or continue? New antithrombotic and anticoagulants Acta Anaesthesiol Belg 52 2001 385 393
2. A.C. Spyropoulos R.M. Bauersachs H. Omran M. Cohen Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy Curr Med Res Opin 22 2006 1109 1122
3. J.D. Nielsen H.M. Rasmussen S.E. Husted The antithrombotic-treated patient Ugeskr Laeger 168 2006 4296 4299
4. A. Tiede Perioperative hemostatic management Chirurg 78 2007 69 79
5. T.T. Horlocker D.J. Wedel H. Benzon Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation) Reg Anesth Pain Med 28 2003 172 197
6. S. Kawaguchi S. Tokutomi A case of epidural hematoma associated with epidural catheterization which occurred on the 12th day after the last medication of ticlopidine hydrochloride Masui 51 2002 526 528
7. G. Hartmann A. Steib B. Ludes J. Ravanello Perforation of the pulmonary artery following Swan-Ganz catheterization Ann Fr Anesth Reanim 7 1988 486 493
8. L.P. Roppolo G.M. Vilke S. Chan Nasotracheal intubation in the emergency department, revisited J Emerg Med 17 1999 791 799
9. W.S. Sim I.S. Chung J.U. Chin Risk factors for epistaxis during nasotracheal intubation Anaesth Intensive Care 30 2002 449 452
10. C. Duvillard M. Ballester P. Romanet Traumatic retropharyngeal hematoma: a rare and critical pathology needed for early diagnosis Eur Arch Otorhinolaryngol 262 2005 713 715
11. K.A. Bauer New anticoagulants Hematology Am Soc Hematol Educ Program 2006 450 456
12. M. Levi R.J. Peters J.J. Piek H.R. Büller New anticoagulants Ned Tijdschr Geneeskd 147 2003 909 915
13. R. Botting COX-1 and COX-3 inhibitors Thromb Res 110 2003 269 272
14. J. Vane R. Botting The mechanism of action of aspirin Thromb Res 110 2003 255 258
15. J. Dörffler-Melly H. Büller M. Koopman M. Prins Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery Cochrane Database Syst Rev 4 2003 CD000536
16. R.A. Lange L.D. Hillis Antiplatelet therapy for ischemic heart disease N Engl J Med 350 2004 277 280
17. T.T. Horlocker D.J. Wedel D.R. Schroeder Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia Anesth Analg 80 1995 303 309
18. F. Huang E. Hong Platelet glycoprotein IIb/IIIa inhibition and its clinical use Curr Med Chem Cardiovasc Hematol Agents 2 2004 187 196
19. I. Ahrens K. Peter C. Bode Use of GPIIb/IIIa inhibitors in cardiovascular medicine Expert Rev Cardiovasc Ther 1 2003 233 242
20. W.H. Chen C.P. Lau Advances in antithrombin therapy for ST-elevation myocardial infarction Chin Med J 116 2003 1760 1763
21. R. Wolfram L. Leborgne E. Cheneau Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention Am J Cardiol 92 2003 1080 1083
22. R. Zahn H. Haubelt S. Bechtloff Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) Herz 28 2003 445 452
23. D.J. Schneider A. Aggarwal Development of glycoprotein IIb/IIIa antagonists: translation of pharmacodynamic effects into clinical benefit Expert Rev Cardiovasc Ther 2 2004 903 913
24. D.K. Cheng C.A. Jackevicius P. Seidelin C. Feindel J.L. Rouleau Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery Can J Cardiol 20 2004 223 228
25. J.T. Pang S. Fort A. Della Siega E.A. Cohen Emergency coronary bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use J Card Surg 17 2002 425 431
26. L.K. von Segesser X. Mueller B. Marty J. Horisberger A. Corno Alternatives to unfractioned heparin for anticoagulation in cardiopulmonary bypass Perfusion 16 2001 411 416
27. R.A. Bernstein J.C. Hemphill Critical care of acute ischemic stroke Curr Neurol Neurosci Rep 1 2001 587 592
28. T. Ammar L.E. Scudder B.S. Colly In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time Circulation 95 1997 614 617
29. H. Dauerman S. Ball R. Goldberg M. Desourdy M. Furman Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention J Thromb Thrombolysis 13 2002 127 132
30. P. Thiagarajan New targets for antithrombotic drugs Am J Cardiovasc Drugs 2 2002 227 235
31. M.R. Aragones A.M. Delgado J.A. Bullones Ram M.A. Prieto Palomino D.M. Arias Garcia C.J. Castillo Extreme thrombocytopenia following abciximab therapy Rev Esp Cardiol 57 2004 885 888
32. P. Nurden G. Clofent-Sanchez C. Jais Delayed immunologic thrombocytopenia induced by abciximab Thromb Haemost 92 2004 820 828
33. J.A. Lown A.S. Hughes P. Cannell Prolonged profound abciximab-associated immune thrombocytopenia complicated by transient multi-specific platelet antibodies Heart 90 2004 e55
34. J.L. Orford D.R. Holmes Jr Abciximab readministration Rev Cardivasc Med 2 2002 67 70
35. K.H. Yeh M.C. Chen H.W. Chang Effect of adjunctive tirofiban therapy on angiographic and clinical outcomes in patients with ST-segment elevated acute myocardial infarction undergoing primary stenting Jpn Heart J 45 2004 31 41
36. D.L. Brown Deaths associated with platelet glycoprotein IIb/IIIa inhibitor treatment Heart 89 2003 535 537
37. M.C. Schneider C. Caliezi M.D. Seeberger Antiplatelet therapy or low-dose heparin and neuraxial anesthesia Acta Anaesthesiol Scand Suppl 111 1997 219 221
38. S.V. Pizzo M.L. Schwartz R.L. Hill P.A. McKee Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin J Clin Invest 51 1972 2841 2850
39. C.L. Wu F.M. Perkins Oral anticoagulant prophylaxis and epidural catheter removal Reg Anesth 21 1996 517 524
40. A.S. Gallus J. Hirsh Antithrombotic drugs: part II Drugs 12 1976 132 157
41. D.G. Sherman Ancrod Curr Med Res Opin 18 Suppl 2 2002 s48 s52
42. S.R. Deitcher Clinical utility of subcutaneous hirudins Am J Health Syst Pharm 60 Suppl 5 2003 S27 S31
43. C.W. Cole B. Shea J. Bormanis Ancrod as prophylaxis or treatment for thromboembolism in patients with multiple trauma Can J Surg 38 1995 249 254
44. C.W. Cole J. Bormanis Ancrod: a practical alternative to heparin J Vasc Surg 8 1988 59 63
45. V.J. Zulys S.J. Teasdale E.R. Michel Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass Anesthesiology 71 1989 870 877
46. M.H. French D.P. Faxon Current anticoagulation options in percutaneous intervention: designing patient-specific strategies Rev Cardiovasc Med 3 2002 176 182
47. D. Hoppensteadt J.M. Walenga J. Fareed R.L. Bick Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation Hematol Oncol Clin North Am 17 2003 313 341
48. N.S. Quinsey A.L. Greedy S.P. Bottomley J.C. Whisstock R.N. Pike Antithrombin: in control of coagulation Int J Biochem Cell Biol 36 2004 386 389
49. W. Lim F. Dentali J.W. Eikelboom M.A. Crowther Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Ann Intern Med 144 2006 673 684
50. J. Stöbe A. Siegemund H. Achenbach C. Preiss R. Preiss Evaluation of pharmacokinetics of Dalteparin in patients with renal insufficiency Int J Clin Pharmacol Ther 44 2006 455 465
51. C. Kani S.L. Markantonis C. Nicolaou N. Maggina Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study J Crit Care 21 2006 79 84
52. P. Neligan Low molecular weight heparins in medicine and anesthesia www.4um.com/tutorials 1999
53. J. Fareed D.A. Hoppensteadt R.L. Bick An update on heparins at the beginning of the new millennium Semin Thromb Hemost 26 Suppl 1 2000 5 21
54. J. Fareed D.A. Hoppensteadt R.L. Bick Management of thrombotic and cardiovascular disorders in the new millennium Clin Appl Thromb Hemost 9 2003 101 108
55. U.R. Desai New antithrombin-based anticoagulants Med Res Rev 24 2004 151 181
56. T.M. Chapman K.L. Goa Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep venous thrombosis Drugs 63 2003 2357 2377
57. T.T. Horlocker Low molecular weight heparin and neuraxial anesthesia Thromb Res 101 2001 V141 V154
58. Y. Gozal S.C. Shapira D. Gozal M. Cohen F. Magora Problems raised by the administration of a peridural block in patients receiving anticoagulant therapy Cah Anesthesiol 39 1991 465 468
59. R.J. Litz M. Hübler T. Koch D.M. Albrecht Spinal-epidural hematoma following epidural anesthesia in the presence of antiplatelet and heparin therapy Anesthesiology 95 2001 1031 1033
60. A. Maclean Antiplatelet therapy, regional anesthesia, and spinal hematomas [Letter] Anesth Analg 81 1995 1116
61. P. Narchi Spinal anesthesia and the use of anticoagulants Best Pract Res Clin Anaesthesiol 17 2003 443 449
62. G.X. Shen Development and current applications of thrombin-specific inhibitors Curr Drug Targets Cardiovasc Haematol Disord 1 2001 41 49
63. T.E. Adams S.J. Everse K.G. Mann Predicting the pharmacology of thrombin inhibitors J Thromb Haemost 1 2003 1024 1027
64. S.I. O'Shea T.L. Ortel E.C. Kovalik Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia Semin Dial 16 2003 61 67
65. J.I. Weitz M. Crowther Direct thrombin inhibitors Thromb Res 106 2002 V275 V284
66. H.K. Breddin Current developments in antithrombotic therapy: the role of antithrombin agents Pathophysiol Haemost Thromb 32 Suppl 3 2002 1 8
67. K.A. Pöschell E. Bucha H.U. Esslinger Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis Kidney Int 65 2004 666 674
68. T.E. Warkentin Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban Thromb Res 110 2003 73 82
69. N. Lubenow S. Selleng H.G. Wollert P. Eichler B. Müllejans A. Greinacher Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use Ann Thorac Surg 75 2003 577 579
70. K. Cochran T.J. DeMartini B.E. Lewis Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia J Invasive Cardiol 15 2003 617 621
71. C.W. Cole J. Bormanis G.K. Luna Ancrod versus heparin for anticoagulation during vascular surgical procedures J Vasc Surg 17 1993 288 292
72. N. Lubenow A. Greinacher Hirudin in heparin-induced thrombocytopenia Semin Thromb Hemost 28 2002 431 438
73. K.G. Fisher V. Liebe R. Hudec Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin Thromb Haemost 89 2003 973 982
74. A. Greinacher N. Lubenow P. Eichler Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia Circulation 108 2003 2062 2065
75. P. Eichler N. Lubenow U. Strobel A. Greinacher Antibodies against lepirudin are polyspecific and recognize epitopes of bivalirudin Blood 103 2004 613 616
76. M. Demir O. Iqbal B. Untch D.A. Hoppenstadt B.S. Gaikwad J. Fareed Escarin clotting time is sensitive to heparinoids: comparison of two different techniques Clin Appl Thromb Hemost 7 2001 38 43
77. M.C. Fabrizio Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass J Extra Corpor Technol 33 2003 117 125
78. T. Fenyvesi L. Jörg J. Harenberg Monitoring of anticoagulant effects of direct thrombin inhibitors Semin Thromb Hemost 28 2002 361 368
79. T. Fenyvesi L. Jörg C. Weiss J. Harenberg Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time Thromb Res 11 2003 89 94
80. S.A. Veach A.M. Franks M.C. Allan Severe anaphylactic reaction after repeated intermittent exposure to lepirudin Pharmacotherapy 27 2007 760 765
81. T.E. Warkentin M.A. Crowther Reversing anticoagulants both old and new Can J Anaesth 49 2002 S11 S25
82. J. Hirsh Current anticoagulant therapy—unmet clinical needs Thromb Res 109 Suppl 1 2003 S1 S8
83. J. Hirsh New anticoagulants Am Heart J 142 Suppl 2 2001 S3 S8
84. J. Ruef H.A. Katus New anticoagulants on the horizon Expert Opin Investig Drugs 12 2003 781 797
85. S.M. Bates J.I. Weitz Emerging anticoagulant drugs Arterioscler Thromb Vasc Biol 23 2003 1491 1500
86. D.P. Chew D.L. Bhatt W. Kimball Bivalirudin provides increasing benefit with decreasing renal function: a meta analysis of randomized trials Am J Cardiol 92 2003 919 923
87. B. Ibrahim Bivalirudin alone in the treatment of acute myocardial infarction J Invasive Cardiol 15 2003 [2 p following 718]
88. J.F. Stella R.E. Stella R.A. Iaffaldano D.J. Stella K.W. Erickson R.C. Bliley 3rd Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction J Invasive Cardiol 16 2004 451 454
89. J.M. Schussler C.S. Cameron A. Anwar Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide Am J Cardiol 94 2004 1417 1419
90. A. Koster T. Fischer M. Gruendel Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation J Cardiothorac Vasc Anesth 17 2003 171 175
91. D.J. Cohen A.M. Lincoff T.A. Lavelle Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from REPLACE-2 trial J Am Coll Cardiol 44 2004 1792 1800
92. S.B. Clayton J.R. Acsell A.J. Crumbley 3rd W.E. Uber Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia Ann Thorac Surg 78 2004 2167 2169
93. F.A. Baciewicz Jr Bivalirudin as alternative to both danaparoid and heparin in off-pump coronary artery bypass grafting J Thoracic Cardiovasc Surg 126 2003 2108 2109
94. J.N. Bott K. Reddy S. Krick Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia Ann Thorac Surg 76 2003 273 275
95. Z. Davis R. Anderson D. Short D. Garber A. Valgiusti Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass Ann Thorac Surg 75 2003 264 265
96. A. Koster D. Chew M. Gründel M. Bauer H. Kuppe B. Spiess Bivalirudin monitored with ecarin clotting time for anticoagulation during cardiopulmonary bypass Anesth Analg 96 2003 383 386
97. L.A. Linkins J.I. Weitz An update on new anticoagulants Curr Drug Targets Cardiovasc Haematol Disord 3 2003 287 300
98. A. Greinacher P. Eichler N. Lubenow V. Kiefel Drug-induced and drug-dependent immune thrombocytopenias Rev Clin Exp Hematol 5 2001 166 200
99. J.P. Hérault A. Bernat F. Roye Pharmacokinetics of new synthetic heparin mimetics Thromb Haemost 87 2002 985 989
100. J. Hirsh N. Heddle J.G. Kelton Treatment of heparin-induced thrombocytopenia: a critical review Arch Intern Med 164 2004 361 369
101. N. Lubenow A. Greinacher Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia Am J Cardiovasc Drugs 1 2001 429 443
102. J. Cossy D. Belotti A short synthesis of argatroban: a potent selective thrombin inhibitor Bioorg Med Chem Lett 11 2001 1989 1992
103. E. Di Cera Thrombin interactions Chest 124 Suppl 3 2003 11S 17S
104. M.E. Carr Jr P. Angchaisuksiri S.L. Carr E.J. Martin Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood Cell Biochem Biophys 39 2003 89 99
105. P.A. Arpino R.K. Hallisey Effect of renal function on the pharmacodynamics of argatroban Ann Pharmacother 38 2004 25 29
106. J.M. Walenga An overview of the direct thrombin inhibitor argatroban Pathophysiol Haemost Thromb 32 Suppl 3 2002 9 14
107. W.E. Dager R.H. White Argatroban for heparin-induced thrombocytopenia in Hepato-renal failure and CVVHD Ann Pharmacother 37 2003 1232 1236
108. Y. Tokuda M. Matsumoto T. Sugita Vascular surgery using argatroban in a patient with a history of heparin-induced thrombocytopenia Circ J 67 2003 889 890
109. P.M. Brown M.J. Hursting Lack of pharmacokinetic interactions between argatroban and warfarin Am J Health Syst Pharm 59 2002 2078 2083
110. A.G. Turpie A.S. Gallus J.A. Hoek A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement Engl J Med 9 2001 619 625
111. K.W. Cleveland Argatroban, a new treatment option for heparin-induced thrombocytopenia Crit Care Nurse 23 2003 61 66
112. A. Greinacher Treatment options for heparin-induced thrombocytopenia Am J Health Syst Pharm 60 Suppl 5 2003 S12 S18
113. J. Harenberg I. Jörg T. Fenyvesi Heparin-induced thrombocytopenia: pathophysiology and new treatment options Pathophysiol Haemost Thromb 32 2002 289 294
114. W.P. Jeske J.M. Walenga Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia Curr Opin Invest Drugs 3 2002 1171 1180
115. L.M. Kondo A.K. Wittkowsky B.S. Wiggins Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia Ann Pharmacother 35 2001 440 451
116. B.E. Lewis D.E. Wallis F. Leya M.J. Hursting J.G. Kelton Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia Arch Intern Med 163 2003 1849 1856
117. T.E. Warkentin A. Greinacher Heparin-induced thrombocytopenia and cardiac surgery Ann Thorac Surg 76 2003 2121 2131
118. K. Furukawa H. Ohteki K. Hirahara Y. Narita S. Koga The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations J Thorac Cardiovasc Surg 122 2001 1255 1256
119. S. Kanemitsu M. Nishikawa K. Onoda Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation J Thorac Cardiovsc Surg 126 2003 428 435
120. H. Ohno M. Higashidate T. Yokosuka Argatroban as an alternative anticoagulant for patients with heparin allergy during coronary bypass surgery Heart Vessels 18 2003 40 42
121. N. Johnston M. Wait L. Huber Argatroban in adult extracorporeal membrane oxygenation J Extra Corpor Technol 34 2002 281 284
122. S. Malherbe B.C. Tsui K. Stobart J. Koller Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII Anesthesiology 100 2004 443 445
123. G. Young Current and future antithrombotic agents in children Expert Rev Cardiovasc Ther 2 2004 523 534
124. J.I. Weitz E.R. Bates Direct thrombin inhibitors in cardiac disease Cardiovasc Toxicol 3 2003 13 25
125. M.A. Cannon J. Butterworth R.D. Riley J.M. Hyland Failure of argatroban anticoagulation during off-pump coronary artery bypass surgery Ann Thorac Surg 77 2004 711 713
126. V. Fuster Oral antithrombins and the future of antithrombotic therapy Rev Esp Cardiol 57 Suppl 1 2004 2 8
127. K.L. Kaplan Direct thrombin inhibitors Expert Opin Pharmacother 4 2003 653 666
128. L. Hrebickova J.J. Nawarskas J.R. Anderson Ximelagatran: a new oral anticoagulant Heart Dis 5 2003 397 408
129. S. Carlsson M. Elg C. Mattsson Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats Thromb Res 107 2002 163 168
130. B.I. Eriksson O.E. Dahl Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors Drugs 64 2004 577 595
131. E.A. Nutescu A.K. Wittkowsky Direct thrombin inhibitors for anticoagulation Ann Pharmacother 38 2004 99 109
132. S. Nylander C. Mattsson Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action Blood Coagul Fibrinolysis 14 2003 159 167
133. S.J. Ho T.A. Brighton Ximelagatran: direct thrombin inhibitor Vasc Health Risk Manag 2 2006 49 58
134. P.F. Boudes The challenges of new drug benefits and risks analysis; lessons from the ximelagatran FDA Cardiovascular Advisory Committee Contemp Clin Trials 27 2006 432 440
135. C.J. Boos G.Y. Lip Ximelagatran: an eulogy Thromb Res 118 2006 301 304
136. K.A. Bauer Selective inhibition of coagulation factors: advances in antithrombotic therapy Semin Thromb Hemost 28 Suppl 2 2003 15 24
137. M.M. Samama G.T. Gerotziafas I. Elalamy M.H. Horellou J. Conard Biochemistry and clinical pharmacology of new anticoagulant agents Pathophysiol Haemost Thromb 32 2002 218 224
138. G. Leone E. Rossi A.M. Leone V. DeStefano Novel antithrombotic agents: indirect synthetic inhibitor of factor Xa and direct thrombin inhibitors. Evidence from clinical studies Curr Med Chem Cardiovasc Hematol Agents 2 2004 311 326
139. J.W. Cheng Fondaparinux: a new antithrombotic agent Clin Ther 24 2002 1757 1769
140. R.C. Gosselin J.H. King K.A. Janatpur W.H. Dager E.C. Larkin J.T. Owings Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing Arch Pathol Lab Med 128 2004 1142 1145
141. M. Tobu O. Iqbal D.A. Hoppensteadt C. Shultz W. Jeske J. Fareed Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests Clin Appl Thromb Hemost 8 2002 325 336
142. P.L. Giangrande Fondaparinux (Arixtra): a new anticoagulant Int J Clin Pract 56 2002 615 617
143. M.M. Samama G.T. Gerotziafas Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux) Thromb Res 109 2003 1 11
144. P. Koch Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux Contact Dermatitis 49 2003 276 280
145. R. Parody A. Oliver J.C. Souto J. Fontcuberta Fondaparinux (Arixtra) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins Hematologica 88 2003 ECR32
146. K.A. Bauer D.W. Hawkins P.C. Peters Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents—the selective factor Xa inhibitors Cardiovasc Drug Rev 20 2002 37 52
147. P. Chang New anticoagulants for venous thromboembolic disease IDrugs 7 2004 50 57
148. A.S. Gallus D.W. Coghlan Heparin pentasaccharide Curr Opin Hematol 9 2002 422 429
149. J.C. Reverter Fondaparinux sodium Drugs Today (Barc) 38 2002 185 194
150. A.G. Turpie B.I. Eriksson M.R. Lassen K.A. Bauer Fondaparinux, the first selective factor Xa inhibitor Curr Opin Hematol 10 2003 327 332
151. A.G. Turpie Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration Thromb Haemost 90 2003 364 366
152. A.G. Turpie K.A. Bauer B.I. Eriksson M.R. Lassen PENTHATHALON 2000 Study Steering Committee Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomized double-blind trial Lancet 359 9139 2002 1721 1726
153. A.H. Tran G. Lee Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery Ann Pharmacother 37 2003 1632 1643
154. M.L. Simoons I.W. Bobbink J. Boland A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study J Am Coll Cardiol 43 2004 2183 2190
155. B.L. Davidson Preparing for new anticoagulants J Thromb Thrombolysis 16 2003 49 54
156. M. Reiter R.A. Bucek N. Koca J. Heger E. Minar PERSIST Idraparinux and liver enzymes: observations from the PERSIST trial Blood Coagul Fibrinolysis 14 2003 61 65
157. N.R. Bijsterveld R. Vink B.E. van Aken Recombinant factor VIIa reserves the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers Br J Haematol 124 2004 635 638
158. van Gogh Investigators H.R. Buller A.T. Cohen Idraparinux versus standard therapy for venous thromboembolic disease N Engl J Med 357 2007 1094 1104